1. Home
  2. IMUX vs EDF Comparison

IMUX vs EDF Comparison

Compare IMUX & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.22

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

EDF

Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

HOLD

Current Price

$4.37

Market Cap

166.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
EDF
Founded
2016
N/A
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
166.0M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
IMUX
EDF
Price
$7.22
$4.37
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $43.09
N/A
AVG Volume (30 Days)
★ 392.8K
161.4K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 38.00
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$4.35
52 Week High
$17.43
$5.67

Technical Indicators

Market Signals
Indicator
IMUX
EDF
Relative Strength Index (RSI) 33.34 30.26
Support Level $6.35 N/A
Resistance Level $8.60 $5.41
Average True Range (ATR) 0.65 0.14
MACD 0.17 -0.02
Stochastic Oscillator 36.89 3.35

Price Performance

Historical Comparison
IMUX
EDF

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

Share on Social Networks: